Since PTPN9 was lower expression in surufatinib-non-response CCA tissues and PTPN9 negatively regulates IGF1R phosphorylation at Y1165/1166, we further evaluated that whether IGF1R bypass activation might be one of the potential mechanisms of resistance to surufatinib in CCA patients. The gene discussed is PTPN9; the disease is cholangiocarcinoma.